Regulation of CDX2 expression in esophageal adenocarcinoma

Molecular Carcinogenesis

Volumn 48, Issue 10, 2009, Pages 965-974

  Vaninetti, Nadine ^a   Williams, Lara ^a   Geldenhuys, Laurette ^a   Porter, Geoffrey A ^a   Guernsey, Duane L ^a   Casson, Alan G ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Adenocarcinoma; Barrett esophagus; CDX2; Esophagus; SOX9; WNT

Indexed keywords

BETA CATENIN; CHOLIC ACID; GLYCOCHOLIC ACID; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX9; ANTINEOPLASTIC AGENT; BILE ACID; CDX2 PROTEIN, HUMAN; GASTROINTESTINAL AGENT; HOMEODOMAIN PROTEIN; MESSENGER RNA; NITRIC OXIDE; SCAVENGER; SOX9 PROTEIN, HUMAN;

ARTICLE; BARRETT ESOPHAGUS; CONTROLLED STUDY; DNA METHYLATION; ESOPHAGEAL ADENOCARCINOMA; GASTROESOPHAGEAL REFLUX; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOCARCINOMA; CELL CULTURE; DRUG EFFECT; DRUG POTENTIATION; ENZYME IMMUNOASSAY; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS TUMOR; GENETICS; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BARRETT ESOPHAGUS; BETA CATENIN; BILE ACIDS AND SALTS; BLOTTING, WESTERN; CELLS, CULTURED; DNA METHYLATION; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; ESOPHAGUS; FREE RADICAL SCAVENGERS; GASTROINTESTINAL AGENTS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; NITRIC OXIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOX9 TRANSCRIPTION FACTOR;

EID: 70349952360     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20549     Document Type: Article

References (58)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trend incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-868.
2. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol Ther 2003;17:655-664.
3. Brown LM, Devesa SS, Chow W-H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage and age. J Natl Cancer Inst 2008;100:1184-1187.
4. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: Scientific review. JAMA 2002;287:1972-1981.
5. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol 2005;3:1-10. (Pubitemid 40092937)
6. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831. (Pubitemid 29142625)
7. Bird-Lieberman EL, Fitzgerald RC. Barrett's esophagus. Gastroenterol Clin N Am 2008;37:921-942.
8. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-973.
9. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-1569. (Pubitemid 38428671)
10. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: Burning questions. Nat Rev Cancer 2003:676-684.
11. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006;55:1810-1818. (Pubitemid 44893583)
12. Beck F. Homeobox genes in gut development. Gut 2002;51:450-454.
13. Guo RJ, Suh ER, Lynch JP. The role of cdx proteins in intestinal development and cancer. Cancer Biol Ther 2004;3:593-601. (Pubitemid 41351093)
14. Quinlan JM, Colleypriest BJ, Farrant M, Tosh D. Epithelial metaplasia and the development of cancer. Biochim Biophys Acta 2007;1776:10-21.
15. Eda A, Osawa H, Yanaka I, et al. Expression of homeobox gene CDX2 precedes that of CDX1 during the progression of intestinal metaplasia. J Gastroenterol 2002;37:94-100. (Pubitemid 34223741)
16. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. J Pathol 2003;199:36-40. (Pubitemid 36054727)
17. Eda A, Osawa H, Satoh K, et al. Aberrant expression of CDX2 in Barrett's epithelium and inflammatory esophageal mucosa. J Gastroenterol 2003;38:14-22. (Pubitemid 36267690)
18. Phillips RW, Frierson HF, Jr., Moskaluk CA. Cdx2 as a marker of epithelial intestinal differentiation in the esophagus. Am J Surg Pathol 2003;27:1442-1447. (Pubitemid 37315196)
19. Moons LM, Bax DA, Kuipers EJ, et al. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004;57:1063-1068.
20. Groisman GM, Amar M, Meir A. Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod Pathol 2004;17:1282-1288. (Pubitemid 39312955)
21. Burnat G, Rau T, Elshimi E, Hahn EG, Konturek PC. Bile acids induce overexpression of homeobox gene CDX-2 and vascular endothelial growth factor (VEGF) in human Barrett's esophageal mucosa and adenocarcinoma cell line. Scand J Gastroenterol 2007:1-6. (Pubitemid 350125549)
22. van Baal JW, Bozikas A, Pronk R, et al. Cytokeratin and CDX-2 expression in Barrett's esophagus. Scand J Gastroenterol 2008;43:132-140. (Pubitemid 351161518)
23. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-1399. (Pubitemid 39472995)
24. Moskaluk CA, Zhang H, Powell SM, Cerilli LA, Hampton GM, Frierson HF, Jr. Cdx2 protein expression in normal and malignant human tissues: An immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-919.
25. Fitzgerald RC. Barrett's oesophagus and oesophageal adenocarcinoma: How does acid interfere with cell proliferation and differentiation. Gut 2005;54:i21-i26.
26. Debruyne PR, Witek M, Gong L, et al. Bile acids induce ectopic expression of intestinal guanylyl cyclase C through nuclear factor-kappaB and Cdx2 in human esophageal cells. Gastroenterology 2006;130:1191-1206.
27. Kazumori H, Ishihara S, Rumi MA, Kadowaki Y, Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in barrett's epithelium. Gut 2006;55:16-25. (Pubitemid 41820630)
28. Hu Y, Jones C, Gellersen O, Williams VA, Watson TJ, Peters JH. Pathogenesis of Barrett esophagus: Deoxycholic acid up-regulates goblet-specific gene MUC2 in concert with CDX2 in human esophageal cells. Arch Surg 2007;142:540-544; discussion 544-545 (Pubitemid 46956401)
29. Hu Y, Williams VA, Gellersen O, Jones C, Watson TJ, Peters JH. The pathogenesis of Barrett's esophagus: Secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells. J Gastrointest Surg 2007;11:827-834.
30. Marchetti M, Caliot E, Pringault E. Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes. J Cell Sci 2003;116:1429-1436. (Pubitemid 36527490)
31. Ikeda H, Sasaki M, Ohira S, et al. Tumor necrosis factor-alpha induces the aberrant expression of mucus core protein-2 in non-neoplastic biliary epithelial cells via the upregulation of CDX2 in chronic cholangitis. Hepatol Res 2008; 38:1006-1017.
32. Liu T, Zhang X, So CK, et al. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 2007;28:488-496. (Pubitemid 46321867)
33. Kawai H, Tomii K, Toyooka S, et al. Promoter methylation downregulates CDX2 expression in colorectal carcinomas. Oncol Rep 2005;13:547-551.
34. Yuasa Y, Nagasaki H, Akiyama Y, et al. Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients. Carcinogenesis 2005;26:193-200. (Pubitemid 40207715)
35. Guo M, House MG, Suzuki H, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer 2007;121:1219-1226. (Pubitemid 47293788)
36. Blache P, van de Wetering M, Duluc I, et al. SOX9 is an intestine crypt transcription factor, is regulated by the wnt pathway, and represses the CDX2 and MUC2 genes. J Cell Biol 2004;166:37-47. (Pubitemid 38931915)
37. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J. Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. Am J Clin Pathol 2000;114:583-590. (Pubitemid 33044398)
38. Osterheld MC, Bian YS, Bosman FT, Benhattar J, Fontolliet C. Beta-catenin expression and its association with prognostic factors in adenocarcinoma developed in Barrett esophagus. Am J Clin Pathol 2002;117:451-456. (Pubitemid 34226082)
39. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Alterations of the wnt signaling pathway during the neoplastic progression of Barrett's esophagus. Oncogene 2006;25:3084-3092. (Pubitemid 43780474)
40. Vaninetti NM, Geldenhuys L, Porter GA, et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma. Mol Carcinog 2008;47:275-285.
41. Clemons NJ, McColl KEL, Fitzgerald RC. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 2007;133:1198-1209.
42. Veugelers PJ, Porter GA, Guernsey DL, Casson AG. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006;19:321-328.
43. Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci USA 2005;102:7565-7570. (Pubitemid 40741011)
44. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 2005;280:8343-8350. (Pubitemid 40349737)
45. Lee EH, Sitaraman K, Schuster D, Rashtchian A. A highly sensitive method for one-step amplification of RNA by polymerase chain reaction. Focus 1997;19:39-44.
46. Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005;104:730-739. (Pubitemid 41113671)
47. Stoner GD, Kaighn ME, Reddel RR, et al. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res 1991;51:365-371.
48. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408. (Pubitemid 34164012)
49. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
50. Steininger H, Pfofe DA, Muller H, Haag-Sunjic G, Fratianu V. Expression of CDX2 and MUC2 in barrett's mucosa. Pathol Res Pract 2005;201:573-5577. (Pubitemid 41363951)
51. Hinoi T, Loda M, Fearon ER. Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem 2003;278:44608-44616. (Pubitemid 37377215)
52. Wicking C, Simms LA, Evans T, et al. CDX2, a human homologue of drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene 1998;17:657-659. (Pubitemid 28402902)
53. Nehra D, Howell P, Williams CP, Pye JK, Beynon J. Toxic bile acids in gastro-oesophageal reflux disease: Influence of gastric acidity. Gut 1999;44:598-602. (Pubitemid 29195903)
54. Bernstein H, Holubec H, Bernstein C, et al. Deoxycholate-induced colitis is markedly attenuated in Nos2 knockout mice in association with modulation of gene expression profiles. Dig Dis Sci 2007;52:628-642. (Pubitemid 46303084)
55. Feagins LA, Zhang HY, Zhang X, et al. Mechanisms of oxidant production in esophageal squamous cell and Barrett's cell lines. Am J Physiol Gastrointest Liver Physiol 2008;294:G411-G417. (Pubitemid 351253330)
56. Casellas F, Mourelle M, Papo M, et al. Bile acid induced colonic irritation stimulates intracolonic nitric oxide release in humans. Gut 1996;38:719-723. (Pubitemid 26167480)
57. Chisaki K, Nakajima T, Iwasawa K, et al. Enhancement of endothelial nitric oxide production by chenodeoxycholic acids in patients with hepatobiliary diseases. Jpn Heart J 2001;42:339-353. (Pubitemid 32894144)
58. Nakajima T, Okuda Y, Chisaki K, et al. Bile acids increase intracellular Ca(2+) concentration and nitric oxide production in vascular endothelial cells. Br J Pharmacol 2000;130:1457-1467.